Breast cancer mortality in the U.S. fell by 41% from 1989 to 2018, yet screening decisions still hinge on tradeoffs that vary by age, risk, and test accuracy. While 74.3% of women ages 50 to 74 reported getting a mammogram within the past 2 years, the same screening pathways also produce false positives around 7% to 10% per round and biopsy positive predictive values often below 30%. This post puts those headline outcomes alongside the sensitivity, recall rates, and modern digital and AI screening performance so you can see what “benefit” actually looks like in real-world programs.
Key Takeaways
- Breast cancer mortality decreased by 41% in the U.S. from 1989 to 2018 (age-adjusted)
- The Cochrane review found mammography screening reduces breast cancer mortality by 15% (meta-analysis of randomized trials)
- A meta-analysis found screening mammography reduces deaths from breast cancer by 19% (randomized evidence)
- 0.23% of women in the U.S. will be diagnosed with breast cancer each year (lifetime risk 1 in 8)
- In the U.S. (Behavioral Risk Factor Surveillance System, 2019), 74.3% of women aged 50–74 reported receiving a mammogram within the past 2 years
- In the U.S. (National Health Interview Survey, 2019), 77.2% of women aged 50–64 reported having a mammogram in the past year
- US Preventive Services Task Force (USPSTF) recommends individual decision-making for biennial screening mammography for women aged 40 to 49
- A meta-analysis estimated false-positive rates for screening mammography at roughly 7%–10% over a round
- In a systematic review, screening mammography specificity was about 89% on average
- A meta-analysis estimated the sensitivity of digital mammography for women aged 50–74 at about 85% (pooled)
- The global breast imaging market was valued at $3.4 billion in 2022 (includes mammography-related imaging technologies)
- The global mammography market size was estimated at $5.5 billion in 2023
- The U.S. mammography equipment market accounted for about $1.2 billion in 2023 (equipment segment estimate)
- In the U.S., Medicare reimburses screening mammography at $..., (carrier pricing varies) (use CMS fee schedule)
- In the U.S., the standard screening mammography HCPCS code is G0204 (diagnostic, bilateral)
In the US, mammography use is high and mortality has fallen, with screening trials showing sizable survival benefits.
Related reading
01 · Category
Effectiveness & Outcomes6 stats
01
Breast cancer mortality decreased by 41% in the U.S. from 1989 to 2018 (age-adjusted)
02
The Cochrane review found mammography screening reduces breast cancer mortality by 15% (meta-analysis of randomized trials)
03
A meta-analysis found screening mammography reduces deaths from breast cancer by 19% (randomized evidence)
04
In the Swedish Two-County Trial, breast cancer screening reduced mortality by 26% compared with control (age group 40–74 years)
05
A randomized study in the UK demonstrated a reduction in breast cancer mortality with mammographic screening (approx. 20–25% in long-term follow-up)
06
The positive predictive value (PPV) for biopsy after a positive mammogram is commonly below 30% in population screening settings (review)
Interpretation
Effectiveness & Outcomes Interpretation
Across Effectiveness and Outcomes, breast cancer mortality has fallen substantially, with major evidence showing mammography screening can reduce deaths by about 15% to 26% in randomized trials and the US age adjusted mortality dropping 41% from 1989 to 2018.
02 · Category
Incidence & Burden1 stats
01
0.23% of women in the U.S. will be diagnosed with breast cancer each year (lifetime risk 1 in 8)
Interpretation
Incidence & Burden Interpretation
In the incidence and burden category, about 0.23% of U.S. women are diagnosed with breast cancer each year, adding up to a lifetime risk of 1 in 8.
03 · Category
Screening Uptake2 stats
01
In the U.S. (Behavioral Risk Factor Surveillance System, 2019), 74.3% of women aged 50–74 reported receiving a mammogram within the past 2 years
02
In the U.S. (National Health Interview Survey, 2019), 77.2% of women aged 50–64 reported having a mammogram in the past year
Interpretation
Screening Uptake Interpretation
For the screening uptake angle, about three quarters of women are getting screened regularly in the US, with 74.3% aged 50–74 reporting a mammogram in the past 2 years and 77.2% aged 50–64 reporting one in the past year.
04 · Category
Guidelines & Recommendations1 stats
01
US Preventive Services Task Force (USPSTF) recommends individual decision-making for biennial screening mammography for women aged 40 to 49
Interpretation
Guidelines & Recommendations Interpretation
For the Guidelines and Recommendations category, the USPSTF emphasizes shared, individualized decision-making for biennial screening mammography starting at age 40 through 49 rather than a one-size-fits-all rule.
05 · Category
Performance Metrics8 stats
01
A meta-analysis estimated false-positive rates for screening mammography at roughly 7%–10% over a round
02
In a systematic review, screening mammography specificity was about 89% on average
03
A meta-analysis estimated the sensitivity of digital mammography for women aged 50–74 at about 85% (pooled)
04
For supplemental ultrasound after a negative mammogram in high-risk women, pooled sensitivity was about 80%
05
For breast MRI in high-risk screening, sensitivity is often reported around 90% (pooled estimates)
06
In a retrospective validation of AI mammography, reading time per case dropped by about 30% (reported)
07
In a UK evaluation, double reading in the NHS achieved sensitivity around 90% for cancer detection (programmatic performance)
08
In screening programs, recall (positive screen) rates are commonly 5%–10% per invitation interval (program metrics review)
Interpretation
Performance Metrics Interpretation
Across performance metrics for breast cancer screening, tests generally balance strong detection with a predictable tradeoff, such as digital mammography sensitivity around 85% with recall rates typically 5% to 10% per invitation and false positives about 7% to 10% per round, while add on high risk tools like ultrasound reach about 80% sensitivity and MRI about 90%.
06 · Category
Market Size7 stats
01
The global breast imaging market was valued at $3.4 billion in 2022 (includes mammography-related imaging technologies)
02
The global mammography market size was estimated at $5.5 billion in 2023
03
The U.S. mammography equipment market accounted for about $1.2 billion in 2023 (equipment segment estimate)
04
The global CAD (computer-aided detection) for breast imaging market reached $0.9 billion in 2023 (estimate)
05
AI-enabled breast imaging software is expected to exceed $1.5 billion globally by 2028 (forecast)
06
Digital mammography equipment represented about 65% of new mammography system sales in 2022 (industry share estimate)
07
Full-field digital mammography (FFDM) systems have been the dominant modality in many markets, replacing film mammography (observed global adoption share: ~80% in 2019)
Interpretation
Market Size Interpretation
The market size for breast cancer screening technologies is expanding quickly as AI-enabled breast imaging is projected to surpass $1.5 billion globally by 2028, building on a $3.4 billion breast imaging market in 2022 and a $0.9 billion CAD segment in 2023.
More related reading
07 · Category
Cost Analysis4 stats
01
In the U.S., Medicare reimburses screening mammography at $..., (carrier pricing varies) (use CMS fee schedule)
02
In the U.S., the standard screening mammography HCPCS code is G0204 (diagnostic, bilateral)
03
The estimated cost-effectiveness of mammography screening is generally reported as under conventional willingness-to-pay thresholds (e.g., <$50,000per QALY in some analyses)
04
Modeling studies often report incremental cost-effectiveness ratios (ICERs) for screening mammography that are commonly below $100,000per QALY for many strategies (systematic review)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, Medicare screening mammography in the U.S. is reimbursed based on CMS fee schedule rates and, across modeling and systematic reviews, mammography screening typically remains cost effective with ICERs often under $100,000 per QALY and sometimes reported below $50,000 per QALY, indicating strong economic value for many strategies.
08 · Category
Guidelines3 stats
01
The U.S. Preventive Services Task Force recommends screening mammography every 2 years for women aged 50–74.
02
Mortality reduction estimates from mammography screening are larger in average-risk settings: an updated Cochrane analysis found a 19% reduction in breast cancer mortality for women invited to screening (randomized trials meta-analysis; reported in 2013 update).
03
In the Swedish National Board of Health and Welfare guidance for breast cancer screening, screening intervals of 2 years are used for organized programs in standard-risk women.
Interpretation
Guidelines Interpretation
Guidelines worldwide emphasize biennial screening, with the US recommending mammography every 2 years for women 50–74 and Swedish standard risk programs using 2 year intervals, while evidence from the 2013 updated Cochrane analysis suggests invited screening can cut breast cancer mortality by about 19% in average-risk settings.
09 · Category
Test Performance5 stats
01
For women with a known BRCA mutation who undergo breast MRI screening, the pooled sensitivity across included studies for detecting breast cancer is about 90%.
02
In population screening, the positive predictive value of a biopsy recommendation after a positive mammogram ranges from 20% to 35% depending on program and definition.
03
In a systematic review, the specificity of digital screening mammography averaged about 89% across studies.
04
In a large retrospective study, the incremental cancer detection rate with DBT compared with FFDM was about 1 additional cancer detected per 1,000 women screened (reported in evaluation studies).
05
In comparative evaluations, DBT can increase recall rates modestly: reported absolute recall increases are typically around 1–3 percentage points versus FFDM (program evaluation studies).
Interpretation
Test Performance Interpretation
From a test performance perspective, the evidence shows strong ability to detect cancer, such as about 90% pooled sensitivity for MRI in BRCA carriers, while population screening trade offs remain measurable with specificity around 89% for digital mammography and only modest gains for DBT, including roughly 1 extra cancer per 1,000 screened and recall increases of about 1 to 3 percentage points.
10 · Category
Program Metrics4 stats
01
In a review of international screening program performance, recall (positive screen) rates commonly fall between 5% and 10% per invitation interval.
02
In the European breast cancer screening program context, typical interval cancer rates are reported around 2–10 per 1,000 women screened per year (range by program and definition).
03
In organized screening, the rate of false positives (defined as non-cancer recall events per round) is commonly reported as 5–10% of invitations resulting in a recall (program-level metric).
04
In a modeling study for U.S. screening strategies, annualized false-positive events decreased when extending screening intervals from annual to biennial, with a relative reduction on the order of 20–30% depending on age and risk group.
Interpretation
Program Metrics Interpretation
From a program metrics perspective, extending screening from annual to biennial can meaningfully reduce the false positive burden, with modeling suggesting a 20 to 30% drop, while recall rates in organized programs typically sit at 5 to 10% per invitation and interval cancer rates hover around 2 to 10 per 1,000 screened each year.
11 · Category
Epidemiology3 stats
01
A systematic review reported that breast density is present at higher levels (heterogeneously/extremely dense) in roughly 40% of women undergoing mammography (pooled prevalence, definitions vary).
02
Dense breast tissue confers higher risk: women with extremely dense breasts have about a 4–6x relative risk of breast cancer compared with women with low breast density (relative risk estimates from cohort meta-analyses).
03
In the U.S., about 10–12% of breast cancers are diagnosed as triple-negative breast cancer (TNBC) among all breast cancers (observational estimates).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, about 40% of women have heterogeneously or extremely dense breasts, and because extremely dense tissue carries roughly a 4 to 6 times higher relative risk of breast cancer, density likely plays a major role in the overall distribution of breast cancer cases.
12 · Category
Industry Trends1 stats
01
In the U.S., about 70% of screening mammograms are performed with digital breast tomosynthesis (DBT) in markets that report tomosynthesis adoption, based on claims-based utilization trends (observational study).
Interpretation
Industry Trends Interpretation
Industry trends in the U.S. show that about 70% of screening mammograms are now performed with digital breast tomosynthesis in markets that report adoption, reflecting rapid uptake of DBT driven by real-world utilization patterns.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Breast Cancer Screening Statistics. Gitnux. https://gitnux.org/breast-cancer-screening-statistics
MLA
Rachel Svensson. "Breast Cancer Screening Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-screening-statistics.
Chicago
Rachel Svensson. 2026. "Breast Cancer Screening Statistics." Gitnux. https://gitnux.org/breast-cancer-screening-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)